Dominic specialises primarily in patent litigation with a focus on life sciences; his science background gives him an excellent grounding in the technical aspects of such disputes. He has experience before the Patent Office, High Court and Court of Appeal as well as experience of Opposition proceedings before the EPO.
Dominic has extensive experience of cross-border litigation in and beyond Europe. This has involved working closely with other lawyers, in-house and external, to ensure alignment with global strategic objectives concerning the defence and enforcement of several portfolios of patents.
In the pharmaceutical sector, Dominic has worked on all aspects of the drug life cycle, from freedom to operate analyses and early-stage risk assessment of generic competition to end-stage litigation, SPCs and anti-trust issues.
Outside patent litigation, Dominic has experience of conducting litigation concerning registered designs and copyright and the issues arising in the tobacco, publishing, gaming and computer gaming industries. He also has experience of other technology-related disputes such as product liability claims before the Technology and Construction Court and the International Court of Arbitration.
Dominic writes regularly on reported patent cases in the UK and at the EPO and is a member of the AIPPI. He is a regular conference speaker and presenter.
MA Natural Sciences, University of Cambridge
PhD Zoology, University of Cambridge
Diploma in Intellectual Property Law and Practice, University of Bristol
- Patents - Who's Who Legal (2018/2017/2016)
- Life Sciences, Patent Litigation - Who's Who Legal (2018)
- Recommended Patent Litigator - Managing Intellectual Property, IP Stars (2017)
- Patent Litigation - IAM Patent 1000 (2017/2016)
- Intellectual property - Legal 500 (2016)
- Pharmaceuticals and Biotechnology - Legal 500 (2015)
- IP Law - Super Lawyers (2015)
"Dominic Adair recently represented biosimilar manufacturer Celltrion in a revocation action – only the second time that a patent case relating to a biosimilar has been brought to trial in the United Kingdom." - IAM Patent 1000 2017
"Cross-border maestro Dominic Adair focuses on pharmaceuticals, with an in-depth understanding of all aspects of the drug’s lifecycle." - IAM Patent 1000 2016
"Recently promoted IP litigation expert Dominic Adair assisted Novartis with the international coordination of its patent litigation relating to its drug Galvus; and advised the same client on the defence of its patents for the cancer medicine Glivec." - Legal 500 2015